Securities & Investment Fraud

Baxter International Inc. Securities Class Litigation

Introduction

Class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX).  If you purchased or otherwise acquired Baxter securities between February 21, 2019 and October 23, 2019, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than January 24, 2020.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the action.  Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market.  We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Baxter investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should use the contact form below or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Baxter Securities Class Litigation

Baxter, based in Deerfield, Illinois, provides a broad portfolio of essential healthcare products, including acute chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, and surgical hemostat and sealant products.

The action alleges that during the Class Period, Baxter and certain of its officers made materially false and/or misleading statements and/or failed to disclose that: (i) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with Generally Accepted Accounting Principles (“GAAP”) and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; 2) the Company lacked effective internal control over its financial reporting; (3) as a result, the Company’s financial statements were misstated and would likely necessitate correction or amendment; (4) due to the Company’s internal investigation, Baxter would not be able to timely file its quarterly report for the period ending September 30, 2019 with the Securities and Exchange Commission (“SEC”) on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Baxter and its officers’ statements about the Company’s business and operations lacked a reasonable basis at all relevant times.

On October 24, 2019, Baxter announced that it “recently began an investigation into certain intra-Company transactions undertaken for the purpose of generating foreign exchange gains or losses,” and that according to the Company, “[t]hese transactions used a foreign exchange rate convention historically applied by the Company that was not in accordance with generally accepted accounting principles (“GAAP”) and enabled intra-Company transactions to be undertaken after the related exchange rates were already known.”  The Company also admitted that these intra-Company transactions had “resulted in certain misstatements in the Company’s previously reported non-operating income related to net foreign exchange gains” and acknowledged that upon completion of its investigation, “the Company expects to either amend its periodic reports previously filed with the SEC to include restated financial statements that correct those misstatements, or include in reports for future periods restated comparative financial statements that correct those misstatements.”  Following this news, the price of Baxter common stock fell $8.87 per share, or 10.1%, from a close of $87.95 per share on October 23, 2019 to close at $79.08 per share on October 24, 2019, on elevated trading volume.

Shareholder Contact Form


First Name (required)

Last Name (required)

Email address (required)

Street Address

City

State

Zip

Telephone

How did you find our site?

Are you currently represented by an attorney?

II. TRANSACTIONS IN BAXTER SECURITIES

Number of shares of Baxter common stock held immediately before the start of Class Period on February 21, 2019:

From February 21, 2019 through October 23, 2019 inclusive, I made the following transactions in Baxter securities:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

During the 90 days after October 23, 2019, I made the following transactions in Baxter securities:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

Comments & questions:

Please sign me up for your Consumer Law newsletter. Yes


About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years.  In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.”  Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.”  In late 2016, Benchmark Litigation named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”